Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GYS1 | P13807 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3083902 | 0.85 | THRB (0.52) | HSD11B1THRBALOX12KMT2ADGAT1 | |
| SCHEMBL13152705 | 0.78 | L3MBTL1 (0.61) | HSD11B1THRBALOX12KMT2ADGAT1 | |
| SCHEMBL3108692 | 0.77 | DGAT1 (0.59) | THRBALOX12KMT2ADGAT1 | |
| SCHEMBL3121161 | 0.77 | DGAT1 (0.59) | THRBALOX12KMT2ADGAT1 | |
| SCHEMBL3100723 | 0.77 | DGAT1 (0.59) | THRBALOX12KMT2ADGAT1CA2 | |
| SCHEMBL4226873 | 0.77 | DGAT1 (0.62) | DGAT1 | |
| SCHEMBL4226872 | 0.77 | DGAT1 (0.62) | DGAT1 | |
| SCHEMBL4226875 | 0.77 | DGAT1 (0.62) | DGAT1 | |
| SCHEMBL3092722 | 0.75 | DGAT1 (0.64) | HSD11B1THRBALOX12KMT2ADGAT1 | |
| SCHEMBL6290808 | 0.75 | CA2 (0.66) | HSD11B1THRBALOX12KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | claimed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BCAT2, BCAT1, FABP4 | HSD11B1 1815/4885THRB 377/4885ALOX12 1611/4885 |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BCAT2, BCAT1, FABP4 | HSD11B1 1815/4885THRB 377/4885ALOX12 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.